中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

抗HCV小分子化合物的研究

李敏然 徐小元

引用本文:
Citation:

抗HCV小分子化合物的研究

DOI: 10.3969/j.issn.1001-5256.2014.06.004
详细信息
  • 中图分类号: R512.63

Recent progress in direct- acting antiviral agents for chronic hepatitis C

  • 摘要: 目前抗HCV治疗的标准疗法是聚乙二醇干扰素(PEG-IFN)联合利巴韦林(RBV),但仍有部分患者不能达到治愈。近年来,靶向针对HCV生活周期中病毒蛋白的小分子化合物的研究得到了迅速发展,小分子化合物联合PEG-IFN、RBV三联治疗可以提高持续病毒学应答率。而对于不能应用/耐受干扰素治疗的慢性丙型肝炎患者,各类小分子化合物之间的联合抗病毒治疗也可取得较好的疗效。因此,认为小分子化合物给今后慢性丙型肝炎治疗带来新的希望。

     

  • [1]De FRANCESCO R, CARFA.Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus[J].Adv Drug Deliv Rev, 2007, 59 (12) :1242-1262.
    [2]FLAMM SL, LAWITZ E, JACOBSON I, et al.Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection[J].Clin Gastroenterol Hepatol, 2013, 11 (1) :81-87.
    [3] ZEUZEM S, ANDREONE P, POL S, et al.Telaprevir for retreatment of HCV infection[J].N Engl J Med, 2011, 364 (25) :2417-2428.
    [4]CUNNINGHAM M, FOSTER GR.Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection[J].Therap Adv Gastroenterol, 2012, 5 (2) :139-151.
    [5]PARK C, JIANG S, LAWSON KA.Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1:a meta-analysis[J].J Clin Pharm Ther, 2014, 39 (1) :14-24.
    [6]GHANY MG, NELSON DR, STRADER DB, et al.An update on treatment of genotype 1 chronic hepatitis C virus infection:2011practice guideline by the American Association for the Study of Liver Diseases[J].Hepatology, 2011, 54 (4) :1433-1444.
    [7]MANNS M, MARCELLIN P, POORDAD F, et al.Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-nave patients:results from QUEST-2, a phaseⅢtrial[C].48th Annual Meeting of the European Association for the Study of the Liver (EASL) , Amsterdam, the Netherlands, 2013.
    [8]RODRIGUEZ-TORRES M, STOEHR A, GANE EJ, et al.Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis[J].Clin Gastroenterol Hepatol, 2013.[Epub ahead of print]
    [9]MARCELLIN P, COOPER C, BALART L, et al.Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection[J].Gastroenterology, 2013, 145 (4) :790-800.
    [10]LAWITZ E, MANGIA A, WYLES D, et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med, 2013, 368 (20) :1878-1887.
    [11] RODRIGUEZ-TORRES M, RODRIGUEZ-ORENGO J, GAGGAR A, et al.Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naive genotype 1-4 HCV-infected patients who are coinfected with HIV[C].IDWeek 2013 (Infectious Diseases Society of America) , San Francisco, CA, 2013.
    [12]POCKROS PJ, JENSEN D, TSAI N, et al.JUMP-C:a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients[J].Hepatology, 2013, 58 (2) :514-523.
    [13]LAWITZ E, RODRIGUEZ-TORRES M, RUSTGI VK, et al.Safety and antiviral activity of ANA598 in combination with pegylated interferon a 2A plus ribavirin in treatment-naive genotype-1chronic HCV patients[C].45th Annual Meeting of the European Association for the Study of the Liver, Vienna (Austria) , 2010.
    [14]SARRAZIN C, ZEUZEM S.Resistance to direct antiviral agents in patients with hepatitis C virus infection[J].Gastroenterology, 2010, 138 (2) :447-462.
    [15]LOHMANN V, HOFFMANN S, HERIAN U, et al.Viral and cellular determinants of hepatitis C virus RNA replication in cell culture[J].J Virol, 2003, 77 (5) :3007-3019.
    [16] APPEL N, ZAYAS M, MILLER S, et al.Essential role of domainⅢof nonstructural protein 5A for hepatitis C virus infectious particle assembly[J].PLoS Pathog, 2008, 4 (3) :e1000035.
    [17]POL S, GHALIB RH, RUSTGI VK, et al.Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection:a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial[J].Lancet Infect Dis, 2012, 12 (9) :671-677.
    [18]FISCHER G, GALLAY P, HOPKINS S.Cyclophilin inhibitors for the treatment of HCV infection[J].Curr Opin Investig Drugs, 2010, 11 (8) :911-918.
    [19]FLISIAK R, PAWLOTSKY J, CRABBE R, et al.Alisporivir (DEB025) plus peg-IFNα2a/ribavirin results in superior sustained virological response (SVR24) in chronic C genotype 1 treatment naive patients[C].Ann Meet Eur Assoc Study Liver, 2011.
    [20]GUEDJ J, YU J, LEVI M, et al.Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in HCV genotype 2/3 patients[J].Hepatology, 2014, 59 (5) :1706-1714.
    [21]COELMONT L, HANOULLE X, CHATTERJI U, et al.DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A[J].PLoS One, 2010, 5 (10) :e13687.
    [22]GANE EJ, STEDMAN CA, HYLAND RH, et al.Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection[J].Gaetroenterology, 2014, 146 (3) :736-743.
    [23]LOK A, GARDINER D, HEZODE C, et al.Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV;NS5A inhibitor) and asunaprevir (ASV;NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) [C].63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) , Boston, MA, 2012.
    [24]SULKOWSKI MS, GARDINER DF, RODRIGUEZ-TORRES M, et al.AI444-040 study group sustained virologic response with daclatasvir plus sofosbuvir±ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) [C].48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, The Netherlands, 2013.
    [25]SARRAZIN C, KIEFFER TL, BARTELS D, et al.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir[J].Gastroenterology, 2007, 132 (5) :1767-1777.
  • 加载中
计量
  • 文章访问数:  2652
  • HTML全文浏览量:  8
  • PDF下载量:  712
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-01-15
  • 出版日期:  2014-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回